Astragalus

Mechanism of action

Proposed mechanisms (with stronger evidence in preclinical models than in humans): - Immunomodulation: astragalus polysaccharides may influence innate immunity receptors (e.g. pattern-recognition receptors) with modulation of signaling pathways such as NF-κB and MAPK, altering the cytokine profile (e.g. IL-6, TNF-α, IL-10) in a context-dependent manner. - Activity on immune cells: increased or normalized phagocytic activity, NK cell function, and lymphocyte proliferation/activation in some models; in humans, results are variable and often based on small studies. - Intestinal barrier: in animal/cellular models, some extracts may reduce permeability and support tight junction proteins (e.g. occludin/claudins/ZO-1) and the mucosal response. - Microbiota: polysaccharides may act as fermentable substrates, with potential increases in SCFA-producing bacteria and modulation of immunoactive metabolites; clinical translation is still incomplete. - Antioxidant/cytoprotective effects: modulation of Nrf2 and reduction of oxidative stress in experimental models, with possible downstream effects on low-grade inflammation.

Supported benefits

• Support for certain immune parameters (e.g. markers of immune function) in specific populations and contexts (moderate)
• Reduction in frequency/duration or severity of symptoms in subjects with recurrent respiratory infections in some studies (heterogeneous in quality and formulation) (limited)
• Potential support for the intestinal barrier and modulation of intestinal inflammation (mainly preclinical evidence; insufficient human data for robust conclusions) (emerging)
• Modulation of the microbiota and metabolites (SCFAs) with possible effects on the gut–immunity axis (preclinical > clinical) (emerging)

Safety & side effects

• Gastrointestinal disturbances (nausea, bloating, diarrhea), especially with higher doses or in sensitive individuals
• Headache or insomnia occasionally reported
• Allergic reactions (rare) possible, especially in individuals sensitive to plants/legumes
• Possible variation in immune parameters (a desired or undesired effect depending on the clinical context)

FAQ

Astragalus and the immune system: does it “stimulate” or “modulate”?

The more accurate term is “immunomodulates”: it can increase or reduce specific inflammatory pathways depending on the biological context, the type of extract, and the baseline condition. This makes the results less predictable than with nutrients that correct deficiencies.

Does it have a direct effect on the gut?

Polysaccharides have limited systemic absorption and may act locally in the intestinal lumen and through the microbiota. In preclinical models, effects on the barrier and inflammation are observed; in humans, direct evidence on permeability/intestinal markers is still insufficient.

Does standardization matter (polysaccharides vs astragaloside IV)?

Yes. Polysaccharides and saponins have different pharmacokinetic and biological profiles. Studies with non-standardized extracts are difficult to compare and to replicate with commercial products.

Is it suitable during immunosuppressive therapy or after transplantation?

In general, this is a context in which use is potentially problematic because of possible interference with the therapeutic objective. Individual clinical evaluation is required.

How long does it take to see effects?

In studies, immune or symptom-related endpoints are often assessed after 4–12 weeks. However, the response is variable and depends on formulation, dose, health status, and individual factors (including the microbiota).